Related Experiment Video
Updated: Jan 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Perspective of using in vitro models to understand immunotherapy-induced cytokine release syndrome
Ethan Perkins1,2, Christopher Cooper2, Emma Lund2
1Institute of Cancer Therapeutics, University of Bradford, Bradford, United Kingdom.
Abstract:
Since the TGN1412 clinical trial failure to predict cytokine release syndrome (CRS) during preclinical trials, alternative in vitro models have become increasingly important for identifying potential adverse outcomes in early drug development. Considering this, in 2019 the IMI2/EU immune safety avatar (imSAVAR) consortium was established, encompassing academic, industry, and regulatory organizations. ImSAVAR aims to deliver a broad range of tools to enhance our ability to assess the efficacy and safety of immunomodulatory therapies. In addition, imSAVAR uses the adverse outcome pathway (AOP) concept to describe immune-related adverse effects, such as CRS, thereby facilitating the discovery of new biological markers for clinical management and prediction of immune-related adverse effects in nonclinical development. ImSAVAR unanimously agreed that CRS and advanced cytokine release assay (CRA) development is a key focus with regards to immunological safety testing and hazard identification. The CRA field has rapidly accelerated in recent years, with the rise of New Approach Methodologies (NAMs) to provide enhanced predictive immunological safety testing within a clinical setting. Here, we provide an up-to-date review of recent developments of advanced, in vitro CRA models, discuss how these advances may impact the future field of nonclinical toxicology and the understanding of immune-related adverse outcomes and offer guidance on appropriate model selection.
Insights
New in vitro models, like advanced cytokine release assays (CRAs), are crucial for predicting immune-related adverse events. These methods improve drug safety testing and clinical management of toxicities such as cytokine release syndrome (CRS).
Area of Science:
- Immunotoxicology
- Drug Development
- In Vitro Toxicology
Background:
- The TGN1412 trial failure highlighted limitations in predicting cytokine release syndrome (CRS) using preclinical models.
- The IMI2/EU immune safety avatar (imSAVAR) consortium was formed to develop tools for assessing immunomodulatory therapy safety.
- Adverse Outcome Pathway (AOP) concepts are utilized to understand and predict immune-related adverse effects.
Purpose of the Study:
- To review recent advancements in in vitro cytokine release assay (CRA) models.
- To discuss the impact of these advanced CRA models on nonclinical toxicology and understanding immune-related adverse outcomes.
- To provide guidance on selecting appropriate in vitro CRA models for safety assessment.
Main Methods:
- Review of recent developments in advanced in vitro CRA models.
- Analysis of the application of New Approach Methodologies (NAMs) in immunological safety testing.
- Exploration of the Adverse Outcome Pathway (AOP) framework for immune-related adverse effects.
Main Results:
- Advanced in vitro CRA models are rapidly evolving, offering enhanced predictive capabilities for immunological safety.
- These models are crucial for hazard identification and improving the prediction of adverse outcomes like CRS.
- The integration of NAMs and AOPs is transforming immunotoxicology and nonclinical safety assessment.
Conclusions:
- Advanced in vitro CRA models are essential for improving the prediction of immune-related adverse events in early drug development.
- These methodologies enhance the understanding and management of toxicities such as CRS.
- Guidance on model selection is provided to optimize nonclinical toxicology and safety testing.
Related Concept Videos
Tumor Immunotherapy
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Understanding the Self
In Vitro Drug Release Testing: Overview, Development and Validation
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Understanding Memory

